MedTrace Logo

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

NCT05036421 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-14

No results posted yet for this study

Summary

The aim of this works is to investigate the effect of genetic polymorphism of snps on human response to treatment with empagliflozin and its correlation with with pharmacokinetic parameters in Egyptian subjects

Conditions

  • Pharmacogenomic
  • Pharmacokinetics

Interventions

DRUG

Empagliflozin 10 milligram

antihyperglycemic medication

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Sara M Shaheen, Assiss. Prof · Ain Shams University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2022-05-20
Completion
2022-05-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05036421 on ClinicalTrials.gov